In a recent disclosure to the Securities and Exchange Commission, Haleon (LON:HLN) plc, a prominent player in the consumer health sector, reported its total number of shares with voting rights. As of the end of August, Haleon confirmed that the total number of ordinary shares issued stands at 9,123,638,944, each with a nominal value of £0.01. Notably, the company holds no ordinary shares in Treasury.
This figure is significant for shareholders and others with notification obligations, as it serves as the denominator for calculating changes in share ownership. Notifications regarding changes in share interests should be directed to the company's secretary via the provided email.
Haleon, which trades on both the London Stock Exchange and the New York Stock Exchange under the ticker HLN, specializes in products across various health categories, including Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals and Supplements. The company is known for its portfolio of established brands such as Advil, Sensodyne, Panadol, and Voltaren, which are underpinned by a foundation of trusted science and innovation.
The announcement, made by Amanda Mellor, Company Secretary of Haleon, confirms the company's compliance with the Disclosure and Transparency Rules of the Financial Conduct Authority. This information is based on a press release statement and reflects the company's status as of August 31, 2024.
In other recent news, Haleon, a global healthcare company, has made significant strides in its operations and strategic planning. The company announced the appointment of two new board members, Alan Stewart and Nancy Avila, who bring a wealth of experience in corporate finance, business transformation, and digital strategy.
In the realm of financial performance, Haleon has reported slight growth in North America for the first half of 2024 and projects an optimistic sales growth outlook for the second half of the year.
Haleon has also been subject to various analyst ratings. Goldman Sachs (NYSE:GS) downgraded the company's stock from "Buy" to "Neutral," citing overvaluation, while Berenberg initiated coverage with a "Buy" rating, anticipating organic sales growth and the successful launch of a new product, Eroxon, in the U.S. market.
Despite facing challenges such as cost inflation and increased advertising spending, Haleon remains confident in its growth prospects. The company plans to buy back shares and has extended its joint venture in China, demonstrating its proactive approach to strategic decision-making. As part of its growth strategy, Haleon is set to launch new products in the Oral Care segment and an erectile dysfunction cream, Eroxon, later in the year. These recent developments reflect a dynamic period for Haleon.
InvestingPro Insights
As Haleon plc continues to navigate the consumer health sector, real-time data from InvestingPro offers a glimpse into the company's financial health and stock performance. Haleon's market capitalization stands at a robust $45.79 billion, reflecting its significant presence in the market. With a price-to-earnings (P/E) ratio of 31.5, the company shows a relatively high valuation compared to earnings, which may be indicative of investor confidence in its future growth prospects.
InvestingPro Tips highlight Haleon's impressive gross profit margins, which are reported at 62.54%, underscoring the company's ability to retain a substantial portion of sales as profit after accounting for the cost of goods sold. Moreover, the stock is currently trading near its 52-week high, with a price that is 99.51% of this peak, signaling strong recent performance. However, it is worth noting that the Relative Strength Index (RSI) suggests Haleon's stock may be in overbought territory, which could be a point of caution for potential investors.
For those looking to delve deeper into Haleon's financials and stock performance, there are more InvestingPro Tips available, providing a comprehensive analysis of the company's outlook. This additional insight can be found at: https://www.investing.com/pro/HLN.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.